Moderna Flu Vaccine Wins Panel Backing; Lilly Expands

The healthcare sector showed positive momentum with select large-cap names advancing amid regulatory progress and capacity expansion announcements. Moderna ($MRNA) closed at $61, gaining 2.79% following favorable advisory committee action, while Bristol Myers Squibb ($BMY) settled at $55.53, up 1.52% as investors weighed the company's pipeline strategy against upcoming patent expirations. The day's developments highlighted the sector's focus on diversifying revenue streams beyond legacy franchises, with particular attention to novel modalities and metabolic disease therapeutics.

Eli Lilly ($LLY) received presidential attention as the Trump administration highlighted the company's $3.5B manufacturing facility, described as a state-of-the-art operation that will create over 1,000 jobs as the company expands weight-loss pill production globally. Analysts project $LLY's global sales will reach $137 billion by 2032, driven primarily by its weight-loss drug franchise. $BMY declared a quarterly dividend of $0.63 per share, payable August 3, 2026, to shareholders of record as of July 2, 2026, while advancing a pipeline of 50 compounds with multiple new medicines targeted for launch by 2030 to offset patent cliff impacts. Merck ($MRK) reported positive Phase 3 results for anti-TL1A antibody tulisokibart in moderately to severely active ulcerative colitis and received FDA approvals expanding KEYTRUDA-WELIREG use in kidney cancer and CAPVAXIVE's indication to higher-risk children and adolescents. Johnson & Johnson ($JNJ) reported strong clinical data for TALVEY combinations in relapsed/refractory multiple myeloma and positive Phase 2/3 ENERGY results for IMAAVY in warm autoimmune hemolytic anemia.

Intuitive Surgical ($ISRG) has faced significant pressure in 2026, with shares down 28% year-to-date despite continued revenue growth for its da Vinci surgical robot platform. Goldman Sachs issued a contrarian call on the stock, going against the grain as Deutsche Bank slashed its target and Bank of America trimmed its outlook on the medical device maker. $JNJ announced broader U.S. availability of its TECNIS PureSee extended depth of focus intraocular lens, reinforcing its position in premium MedTech optics. Illumina ($ILMN) expanded its Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, as an independent director effective June 16, 2026, aligning the genomics company with expertise in drug discovery, clinical development, and precision medicine across cardiometabolic, immunology, and neuroscience fields.

Moderna ($MRNA) received a unanimous advisory committee vote supporting mRNA-1010, its influenza vaccine candidate, for adults aged 50 and older, marking a significant regulatory milestone for the mRNA platform beyond COVID-19 applications. The FDA advisory panel's unanimous backing positions the vaccine for potential approval in the coming months. Pfizer ($PFE) CEO Albert Bourla commented that pandemic-era urgency allowed an eight-month COVID vaccine timeline, noting that regulators and governments have since reverted to more conservative approaches. The regulatory environment continues to balance innovation speed with safety standards as companies push novel modalities through the approval pipeline.

The sector faces a pivotal period as multiple companies work to diversify revenue streams ahead of significant patent expirations. Bristol Myers Squibb ($BMY) is targeting multiple new medicine launches by 2030 from its 50-compound pipeline to address upcoming loss of exclusivity events. Merck ($MRK) continues advancing its immunology portfolio beyond oncology with late-stage assets in inflammatory diseases. Flagship Pioneering, the scientific innovation company behind Moderna ($MRNA), announced a strategic collaboration with Lean Business Services Company to advance healthcare innovation and AI-enabled biomedical research in Saudi Arabia, expanding the reach of novel therapeutic modalities into new markets.